We want to provide some insight into our company's values in an ongoing series on Halozyme's Insights webpage. This series is an opportunity to continue to build our connectivity and community as we invite you to explore our core values, what they mean and how they continue guiding our actions as we pursue our mission to improve patient experiences and outcomes.
At Halozyme, we have five core values, selected in 2014, that drive everything we do, and they are the thread between us. As we work toward our mission of improving patient experiences and outcomes, these values represent the essence of our culture.
We Respect and Value the Team
We Focus on Patients
We Do the Right Thing
We are All Empowered and Accountable
We Innovate
We welcome you into this community that we are so proud to be a part of and encourage you to learn more about our company, our team and the values that are helping us blaze a trail toward a healthier future. We look forward to sharing a more in-depth look at our company's core values and how our incredible team members exemplify them daily through this ongoing Halozyme Insights series.
Enjoy.
Helen Torley, M.B. Ch. B., M.R.C.P.
President and CEO
This series will give you an employee's perspective of what the values mean to them and how it impacts how they approach each and every day. If you are inspired to be part of this forum, we invite you to view our career page to learn more.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Halozyme Therapeutics Inc. published this content on 05 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 April 2022 00:03:04 UTC.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Companyâs ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.